Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹94.80
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹466.62M
Enterprise Value₹1.37B
Total Cash (Recent Filing)₹96.75M
Total Debt (Recent Filing)₹949.21M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model DiversificationMangalam's B2B model supplying specialty chemicals and APIs to both domestic and international customers provides durable demand diversification. Serving pharma and chemical supply chains reduces single-market exposure and supports stable order flow over multiple months, aiding revenue resilience.
Manageable Leverage / Balance Sheet StabilityThe company’s balance sheet shows a controlled debt-to-equity profile and consistent equity, offering a financial cushion during cyclical downturns. Manageable leverage supports working capital and compliance spending in a capital-intensive manufacturing business, preserving operational continuity.
Improving Operating Cash GenerationImproved operating cash flow versus net income indicates stronger cash conversion from core operations. For a specialty chemicals/API manufacturer, reliable operating cash supports raw material purchases, quality controls and debt servicing, strengthening the firm's ability to weather medium-term demand volatility.
Bears Say
Steep Revenue DeclineA ~31% revenue decline signals sustained demand or execution issues that undermine scale economics. For a B2B chemical/API supplier, reduced volumes erode fixed-cost absorption and pricing leverage, pressuring margins and making multi-month recovery dependent on rebuilding customer orders or new contract wins.
Contracting Margins And ProfitabilityContracting EBIT/EBITDA margins indicate margin compression from cost pressures or weaker pricing power. Persistent margin deterioration reduces internal reinvestment capacity, heightens sensitivity to input-cost swings, and lowers the company's ability to fund quality, compliance and growth initiatives over the medium term.
Rising Debt And Inconsistent Free Cash FlowAn increase in total debt combined with inconsistent free cash flow raises refinancing and liquidity risks. In a manufacturing context, this constrains capex and working capital flexibility needed for regulatory compliance and customer qualification, making recovery and long-term investments more challenging.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹94.80 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹466.62M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is May 27, 2026 which is in 27 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Jan 15, 2026. The company reported -₹6.214 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.214.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹6.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―